AbbVie to Host Second-Quarter Earnings Conference Call

            AbbVie to Host Second-Quarter Earnings Conference Call

  PR Newswire

  NORTH CHICAGO, Illinois, July 23, 2014

NORTH CHICAGO, Illinois, July 23, 2014 /PRNewswire/ --

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR
INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE
A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.

AbbVie (NYSE: ABBV) will announce its second-quarter 2014 financial results on
Friday, July 25, 2014, before the market opens.

AbbVie will host a live webcast of the earnings conference call at 8 a.m.
Central time (9 a.m. Eastern). It will be accessible through AbbVie's Investor
Relations website at www.abbvieinvestor.com .

Conference Call dial-in instructions:US toll free: 866-617-1526UK toll free:
0800-279-9630International: 001-210-795-0624Passcode: AbbVie

In accordance with Rule 30.4 of the Takeover Code, a copy of this announcement
will be available on AbbVie's website at
http://www.abbvieinvestor.com/phoenix.zhtml?c=251551&p=irol-disclaimer-documents
.

About AbbVie AbbVie is a global, research-based biopharmaceutical company
formed in 2013 following separation from Abbott Laboratories. The company's
mission is to use its expertise, dedicated people and unique approach to
innovation to develop and market advanced therapies that address some of the
world's most complex and serious diseases. AbbVie employs approximately 25,000
people worldwide and markets medicines in more than 170 countries. For further
information on the company and its people, portfolio and commitments, please
visit www.abbvie.com . Follow @abbvie on Twitter or view careers on our
Facebook or LinkedIn page.

Disclosure requirements of the Takeover Code Under Rule 8.3(a) of the Takeover
Code, any person who is interested in 1% or more of any class of relevant
securities of an offeree company or of any securities exchange offeror (being
any offeror other than an offeror in respect of which it has been announced
that its offer is, or is likely to be, solely in cash) must make an Opening
Position Disclosure following the commencement of the offer period and, if
later, following the announcement in which any securities exchange offeror is
first identified. An Opening Position Disclosure must contain details of the
person's interests and short positions in, and rights to subscribe for, any
relevant securities of each of (i) the offeree company and (ii) any securities
exchange offeror(s). An Opening Position Disclosure by a person to whom Rule
8.3(a) applies must be made by no later than 3.30 pm (London time) on the 10th
business day following the commencement of the offer period and, if
appropriate, by no later than 3.30 pm (London time) on the 10th business day
following the announcement in which any securities exchange offeror is first
identified. Relevant persons who deal in the relevant securities of the
offeree company or of a securities exchange offeror prior to the deadline for
making an Opening Position Disclosure must instead make a Dealing Disclosure.

Under Rule 8.3(b) of the Takeover Code, any person who is, or becomes,
interested in 1% or more of any class of relevant securities of the offeree
company or of any securities exchange offeror must make a Dealing Disclosure
if the person deals in any relevant securities of the offeree company or of
any securities exchange offeror. A Dealing Disclosure must contain details of
the dealing concerned and of the person's interests and short positions in,
and rights to subscribe for, any relevant securities of each of (i) the
offeree company and (ii) any securities exchange offeror, save to the extent
that these details have previously been disclosed under Rule 8. A Dealing
Disclosure by a person to whom Rule 8.3(b) applies must be made by no later
than 3.30 pm (London time) on the business day following the date of the
relevant dealing. Disclosures are therefore required in the shares of AbbVie
and Shire plc.

If two or more persons act together pursuant to an agreement or understanding,
whether formal or informal, to acquire or control an interest in relevant
securities of an offeree company or a securities exchange offeror, they will
be deemed to be a single person for the purpose of Rule 8.3. Opening Position
Disclosures must also be made by the offeree company and by any offeror and
Dealing Disclosures must also be made by the offeree company, by any offeror
and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and
8.4).Details of the offeree and offeror companies in respect of whose relevant
securities Opening Position Disclosures and Dealing Disclosures must be made
can be found in the Disclosure Table on the Takeover Panel's website at
www.thetakeoverpanel.org.uk , including details of the number of relevant
securities in issue, when the offer period commenced and when any offeror was
first identified. You should contact the Takeover Panel's Market Surveillance
Unit on +44 (0)20 7638 0129 if you are in any doubt as to whether you are
required to make an Opening Position Disclosure or a Dealing Disclosure.

No Offer or Solicitation This release is provided for informational purposes
only and does not constitute an offer to sell, or an invitation to subscribe
for, purchase or exchange, any securities or the solicitation of any vote or
approval in any jurisdiction, nor shall there be any sale, issuance, exchange
or transfer of securities in any jurisdiction in contravention of applicable
law.

Additional Information and Where to Find it In furtherance of a potential
combination involving AbbVie, Shire plc and AbbVie Private Limited
("Holdco"), Holdco intends to file with the SEC a registration statement on
Form S-4 containing a Proxy Statement of AbbVie that will also constitute a
Prospectus of Holdco relating to the Holdco Shares to be issued to AbbVie
stockholders in the combination. In addition, AbbVie, Holdco and Shire may
file additional documents with the SEC. INVESTORS AND SECURITY HOLDERS OF
ABBVIE AND SHIRE ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS, AND OTHER
DOCUMENTS FILED WITH THE SEC IN CONNECTION WITH THE TRANSACTION CAREFULLY AND
IN THEIR ENTIRETY, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Those
documents, if and when filed, as well as AbbVie's and Holdco's other public
filings with the SEC may be obtained without charge at the SEC's website at
www.sec.gov , at AbbVie's website at www.abbvieinvestor.com . It is expected
that the Holdco shares to be issued to Shire shareholders under a scheme of
arrangement will be issued in reliance upon the exemption from the
registration requirements of the Securities Act of 1933, as amended, provided
by Section 3(a)(10) thereof.

Participants in the Solicitation AbbVie, its directors and certain of its
executive officers may be considered participants in the solicitation of
proxies in connection with the transactions contemplated by the Proxy
Statement/Prospectus. Information about the directors and executive officers
of AbbVie is set forth in its Annual Report on Form 10-K for the year ended
December 31, 2013, which was filed with the SEC on February 21, 2014, and its
proxy statement for its 2014 annual meeting of stockholders, which was filed
with the SEC on March 24, 2014. Other information regarding potential
participants in the proxy solicitations and a description of their direct and
indirect interests, by security holdings or otherwise, will be contained in
the Proxy Statement/Prospectus when it is filed.

Forward-Looking Statements This announcement contains certain forward-looking
statements with respect to a possible combination involving AbbVie and Shire.
The words "believe," "expect," "anticipate," "project" and similar
expressions, among others, generally identify forward-looking statements.
These forward-looking statements are subject to risks and uncertainties that
may cause actual results to differ materially from those indicated in the
forward-looking statements. Such risks and uncertainties include, but are not
limited to, the possibility that a possible combination will not be pursued,
failure to obtain necessary regulatory approvals or required financing or to
satisfy any of the other conditions to the possible combination, adverse
effects on the market price of AbbVie Shares and on AbbVie's or Shire's
operating results because of a failure to complete the possible combination,
failure to realise the expected benefits of the possible combination, negative
effects relating to the announcement of the possible combination or any
further announcements relating to the possible combination or the consummation
of the possible combination on the market price of AbbVie shares or Shire
shares, significant transaction costs and/or unknown liabilities, general
economic and business conditions that affect the combined companies following
the consummation of the possible combination, changes in global, political,
economic, business, competitive, market and regulatory forces, future exchange
and interest rates, changes in tax laws, regulations, rates and policies,
future business combinations or disposals and competitive developments. These
forward-looking statements are based on numerous assumptions and assessments
made in light of AbbVie's or, as the case may be, Shire's experience and
perception of historical trends, current conditions, business strategies,
operating environment, future developments and other factors it believes
appropriate. By their nature, forward-looking statements involve known and
unknown risks and uncertainties because they relate to events and depend on
circumstances that will occur in the future. The factors described in the
context of suchforward-looking statements in this announcement could cause
AbbVie's plans with respect to Shire, AbbVie's or Shire's actual results,
performance or achievements, industry results and developments to differ
materially from those expressed in or implied by such forward-looking
statements. Although it is believed that the expectations reflected in such
forward-looking statements are reasonable, no assurance can be given that such
expectations will prove to have been correct and persons reading this
announcement are therefore cautioned not to place undue reliance on these
forward-looking statements which speak only as at the date of this
announcement. Additional information about economic, competitive,
governmental, technological and other factors that may affect AbbVie is set
forth in Item 1A, "Risk Factors," in AbbVie's 2013 Annual Report on Form 10-K,
which has been filed with the SEC, the contents of which are not incorporated
by reference into, nor do they form part of, this announcement. Neither AbbVie
nor Shire undertakes any obligation to release publicly any revisions to
forward-looking statements as a result of subsequent events or developments,
except as required by law.

Website: http://www.abbvie.com
Contact: Media: Adelle Infante, (847) 938-8745; Investors: Liz Shea, (847)
935-2211
 
Press spacebar to pause and continue. Press esc to stop.